The US Food and Drug Administration perspective on cancer biomarker development
- 1 July 2006
- journal article
- opinion
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 6 (7) , 565-571
- https://doi.org/10.1038/nrc1911
Abstract
Despite the intense interest in biomarker development for cancer management, few biomarker assays for diagnostic uses have been submitted to the US Food and Drug Administration (FDA). What challenges must researchers overcome to bring cancer-detection technologies to the market and, therefore, into clinical use?Keywords
This publication has 30 references indexed in Scilit:
- Operating Characteristics of Prostate-Specific Antigen and Verification BiasPublished by American Medical Association (AMA) ,2005
- Pancreatic Cancer: Novel Approaches to Diagnosis and TherapyGastroenterology, 2005
- Realizing the Promise of Genomics in Biomedical ResearchPublished by American Medical Association (AMA) ,2005
- Genomic and Proteomic Profiling of Lung Cancers: Lung Cancer Classification in the Age of Targeted TherapyJournal of Clinical Oncology, 2005
- New Developments in the Staging of MelanomaCancer Investigation, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Spectrum bias: a quantitative and graphical analysis of the variability of medical diagnostic test performanceStatistics in Medicine, 2003
- Reliability of Tissue Microarrays in Detecting Protein Expression and Gene Amplification in Breast CancerLaboratory Investigation, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Phases of Biomarker Development for Early Detection of CancerJNCI Journal of the National Cancer Institute, 2001